Investor Newsletter

Issue 01 2017

MicroPort

First Indian Rate Contract Kicks Off in 2017

On January 4, MicroPort Scientific India Private Limited ("MicroPort® Scientific India"), the Indian subsidiary of MicroPort Scientific Corporation ("MicroPort® Scientific"), announced that it successfully got the first annual rate contract for its innovative Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") from Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, an Institute of National Importance under the Department of Science and Technology, Government of India.

Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum is a prestigious Indian government hospital that offers advanced treatment using modern technologies in several specialized areas such as interventional radiology, cardiac electrophysiology, deep brain stimulation for movement disorders, epilepsy surgery, pediatric cardiac surgery, base of skull and vascular surgeries, to name a few. The institute has excellent facilities and teams of professionals dedicated to the development of innovative biomedical devices and products, evaluation of medical devices to global specifications, training in novel medical specialties and research in medical and public health areas of social relevance.

Founded on August 11, 2016, the Indian subsidiary aims to serve the Indian patients with high-quality research-based medical solutions at affordable prices. Its first Indian rate contract means the innovative product Firehawk™ was recognized by Indian experts and will earn a place in the India market.

"India is one of the most important strategic markets for MicroPort® Scientific, and we are extremely pleased to see our star product Firehawk® recognized by local experts," said Dr. Linda Lin, Vice President of International Business. "By constant endeavor of the whole team, we believe our products will benefit more overseas patients."

Mr. Riyaz Desai, Managing Director of MicroPort® Scientific India, said: "As a new member of MicroPort® Scientific, the Indian subsidiary aims to serve the Indian patients with high-quality research-based medical solutions at affordable prices. MicroPort® is committed to save and reshape many lives and improve quality of life of Indian patients. This first rate contract from a prestigious Indian government hospital signifies an auspicious start of business development of MicroPort® in Indian market".

India has the third largest amount of PCI cases in the world, and the market is experiencing rapid development in recent years. The first rate contract from a famous local government hospital marks a good beginning of market expansion of MicroPort® Scientific in India, to bring more ideal solutions to Indian patients who suffer from cardiovascular diseases.

Dongguan Kewei Wins the Second Prize of State Science and Technology Progress Award for the Project "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery"

On January 9, Dongguan Kewei Medical Instrument Co., Ltd. ("Dongguan Kewei"), a wholly owned subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") won the second prize of State Science and Technology Progress Award together with the Fourth Military Medical University for the project "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" they jointly developed. A total of 33 projects of healthcare and medical industry received the State Science and Technology Awards, according to the list released during the 2016 National Science and Technology Award Ceremony.

Funded by the National Key Technology Research and Development Program of China during the "10th Five-Year Plan," the project "New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" is a fruit of series of studies conducted by Dongguan Kewei and the Fourth Military Medical University on the new technologies, new devices, new products and new strategies of minimally invasive cardiac surgery. The project team took the lead in developing the new technology of cardiovascular disease interventional therapy guided by transthoracic ultrasound. They are also the first to use total endoscopic cardiac surgery techniques and created new technologies of minimally invasive cardiac surgery compound operation, as well as adenosyl-CTRP myocardial preservation. They established a new system of minimally invasive cardiac surgery technologies to carry out the conversion from open surgery repair to minimally invasive therapy with the rate of minimally invasive surgery increased to 56%. They treated 35,959 cases of cardiac diseases with the new technology in 64 top hospitals in China and achieved the success rate of 99.6%. In addition, the team developed the new type of occlude for the minimally invasive cardiac surgery and designed innovative arteriovenous catheters, which are also the main products and key technologies of Dongguan Kewei with two national invention patents and 33 patents for inventions, utility models and design.

MicroPort

MicroPort® Re-awarded Shanghai Five-Star Credit Enterprise

MicroPort® was recently selected as "Shanghai Five-Star Credit Enterprise" by Shanghai Credibility Construction Program Committee under Shanghai Municipal Government. MicroPort® was awarded the highest honor of Shanghai Credibility Construction Program for the second consecutive year.

Under the direction of 20 departments of Shanghai Municipal Government including Shanghai Publicity Department, Shanghai Civilization Office, Shanghai Municipal Commission of Economy and Information, Shanghai Credibility Construction Program is designed to promote the construction of Shanghai credibility system and improve the intangible infrastructure of Shanghai's economic and social development.

Integrity is one of MicroPort®'s eight key values and the pursuit of excellence has been deeply rooted in MicroPort's corporate culture. In this selection, MicroPort® obtained the highest AAA rating in the credibility assessment report issued by independent third parties, with its scores of every indicator on top of all the candidates. This five-star award showed that MicroPort®'s effort in building up an integrity system in the company was fully recognized by the committee and the society.

MicroPort® Endovascular and MicroPort® EP Awarded the Title of "2016 Shanghai Specialized, Sophisticated, Distinctive, Innovative SMEs"

On January 9, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") and Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP"), two subsidiaries of MicroPort®, were awarded the title of "2016 Shanghai Specialized, Sophisticated, Distinctive, Innovative Small- and Medium-sized Enterprises ("SMEs")" by Shanghai Municipal Commission of Economy and Informatization.

China's SMEs can only achieve transformation and upgrading by becoming specialized, sophisticated, distinctive and innovative. Thus, every year, Shanghai government names several companies with large development potential the "Specialized, Sophisticated, Distinctive, Innovative SMEs." "Specialized" requires the SME to be dedicated to its core business and ranking top 10 in its market segment in China. "Sophisticated" refers to sophisticated production, management or service of the company. "Distinctive" means the awarding enterprise should have some distinctive, unique features or products. "Innovative" stands for innovative technologies or management, which produces new competitive advantages for the SME. This honorable title will win SMEs more support for the weak links in their development in terms of technological innovation, market expansion, brand establishment and company management.

MicroPort® Endovascular and MicroPort® EP were respectively founded in 2012 and 2010 in Shanghai. Their devices are widely used in China's top hospitals and have been exported to many overseas countries and regions. The title of "2016 Shanghai Specialized, Sophisticated, Distinctive, Innovative SMEs" once again signifies the government's recognition on the innovative achievement of MicroPort® Endovascular and MicroPort® EP, which will definitely fuel their motivation for growth and development.



Hercules® Stent Graft and Delivery System of MicroPort® Endovascular Awarded 2016 Shanghai Top-Brand Product

On December 31, Hercules® Stent Graft and Delivery System, in-house developed by MicroPort® Endovascular, was awarded 2016 Shanghai Top-Brand Product, according to a list released by Shanghai Top Brand Recommendation Committee of Shanghai Municipal Bureau of Quality and Technical Supervision. The award is to honor well-known products and brands with industry-leading position, high customer satisfaction and great development potential.

Shanghai Top-Brand Products are selected by Shanghai Top Brand Recommendation Committee of Shanghai Municipal Bureau of Quality and Technical Supervision, based on the company's core competitiveness, industry position, strategy of building independent brands, innovation sustainability, R&D input, innovative development strategy, as well as the role it plays in driving the industry development. This honorable title signifies government recognition in the brand image of Hercules® Stent Graft and Delivery System as well as the overall performance of MicroPort® Endovascular.



Hercules® Stent Graft and Delivery System is one of the core products in-house developed by MicroPort® Endovascular. Hercules® products align with China and Shanghai's development policies of the bioengineering and pharmaceutical industry, and were listed as Shanghai's first batch of independently innovated products. Hercules® products include Hercules® Thoracic Aortic Aneurysm Stent Graft and Delivery System and Hercules® Abdominal Aortic Aneurysm Stent Graft and Delivery System, both are first of its kind in China, respectively designed for the treatment of thoracic aortic aneurysm and abdominal aortic aneurysm. Since market launch, Hercules® products demonstrated outstanding clinical performance and have saved around 30,000 patients with aortic diseases.

MicroPort



Firesorb® Displayed in Taiwan Transcatheter Therapeutics 2017

From January 7 to January 8, MicroPort® in-house developed innovative product Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®") was displayed in the annual meeting "Taiwan Transcatheter Therapeutics" ("TTT 2017") in Taibei, Taiwan. During the congress, Professor Chaowei Mu of Fuwai Hospital of Chinese Academy of Medical Sciences was invited by MicroPort® to release the six-month follow-up results of Firesorb® FUTURE-I Clinical Trial, which was well received by attendees.

During this year's congress, Professor Chaowei Mu released the six-month clinical, angiographic, IVUS, and OCT results of Firesorb® FUTURE-I Clinical Trial. The clinical trial enrolled 45 patients and the primary endpoint is 30-day target lesion failure, including cardiac death, myocardial infarction of target vessel and TLR (Target lesion Revascularization) resulted from ischemia. The attendees spoke highly of Firesorb®'s safety, efficacy, and its unique design. As the second-generation fully bioresorbable scaffold, Firesorb® features thinner strut that lowers the crossing profile, shortens the bio-degradation time and reduces the risk of postoperative thrombosis. In Firesorb®'s target-eluting design, the drug only retains on one surface that contacts blood vessels, with 60% less drug loadings compared to similar products. Such design reduces the dose of drug, enhances the efficiency of the treatment, and prevents a large amount of drug residual from remaining in the body for a long time, while achieving the same clinical efficacy as other bioresorbable scaffolds.

MicroPort

MicroPort® Endovascular Attends 8th Fuwai Aortic Diseases Treatment Symposium

From January 13 to January 15, MicroPort® Endovascular attended the 8th Fuwai Aortic Diseases Treatment Symposium held in Beijing Fuwai Hospital, and displayed several devices including CRONUS™ Surgical Stent-Graft System ("CRONUS™"), Hercules™-T Low Profile Stent Graft and delivery system ("Hercules™-T"), and Castor™ Branched Aortic Stent Graft and delivery system ("Castor™").

On January 14, Professor Zaiping Jing of Shanghai Changhai Hospital of the Second Military Medical University delivered a speech on the advancement of endovascular minimally invasive treatment of ascending aortic dissection. He pointed out that the Castor™ system in-house developed by MicroPort® Endovascular has epoch-making significance in the endovascular treatment. Professor Jing also mentioned that he looks forward to seeing the market launch of Castor™ to benefit more patients.

Meanwhile, many attendees were attracted to visit MicroPort® Endovascular booth in which it displayed the main features and operating procedures of several kinds of thoracic aortic products, enabling the visitors to get a deeper understating in MicroPort® Endovascular products.

MicroPort

MSC Attends 2017 International Cardiac Pacing Conference

From January 13 to January 15, MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of MicroPort® and Italy-based Sorin Group, attended the 2017 International Cardiac Pacing Conference & the 9th China Cardiac Pacing Summit that was held in Haikou of Hainan Province and meanwhile delivered a speech in the session of "R&D and Application of Domestically Made Cardiac Pacemaker" on January 14.

In the session of "R&D and Application of Domestically Made Cardiac Pacemaker," MSC gave a speech introducing the R&D progress of MSC products and sharing the latest advancement of domestically made pacemakers with experts in attendance. In the following discussion section, several experts and MSC representative had active interaction on question interesting to the attendees.

As the domestically made pacemaker is gaining wider attention, MSC will take advantage of such trend to revolutionize China's pacemaker industry from "Made-in-China" to "Made-in-China + Innovated-in-China." MSC will strive for innovative product R&D and keep on enhancing its innovative capabilities in order to meet the needs of China's physicians and patients, and enable more patients to benefit from devices of world-class quality at more affordable price, and thereby to promote the use of domestically made pacemakers.

Investor Newsletter

Issue 01 2017

MicroPort

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & Senior Director of External Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com